The Ovarian Cancer Connection
A 2021 analysis from the NIEHS Sister Study (White et al., Carcinogenesis) found that frequent use of hair straighteners (>4 times/year) was associated with a 2.19x increased risk of ovarian cancer (HR 2.19, 95% CI: 1.12–4.27). EDCs in hair relaxers — particularly phthalates and parabens — disrupt ovarian function and promote carcinogenesis through estrogen pathway interference.
Why Ovarian Cancer Is Particularly Dangerous
Ovarian cancer is the fifth-leading cause of cancer death among women. It is often diagnosed at advanced stages because early symptoms (bloating, pelvic pain, feeling full quickly) are vague and easily attributed to other conditions. The 5-year survival rate for Stage III/IV ovarian cancer is approximately 30%.
The Talcum Powder Parallel
The hair relaxer ovarian cancer claims parallel the massive talcum powder litigation against Johnson & Johnson. In both cases: a consumer product marketed to women contained undisclosed carcinogenic substances, chronic genital-area exposure increased ovarian cancer risk, and the manufacturer failed to warn despite available evidence. J&J's $6.5 billion settlement provides a direct benchmark.
Documenting Your Ovarian Cancer Claim
Key evidence: pathology reports confirming ovarian cancer type and stage, surgical records (debulking surgery, oophorectomy), chemotherapy records, CA-125 blood test results, detailed history of hair relaxer product use and frequency.
Scientific Evidence
Hair Relaxer Use and Risk of Uterine Cancer in the Black Women's Health Study
Bertrand KA, Coogan PF, Palmer JR (2023). Environmental Research
View on PubMed→Use of Straighteners and Other Hair Products and Incident Uterine Cancer
Chang CJ, O'Brien KM, Keil AP, Gaston SA, Jackson CL, Sandler DP, White AJ (2022). Journal of the National Cancer Institute
View on PubMed→Use of Hair Products in Relation to Ovarian Cancer Risk
White AJ, Sandler DP, et al. (2021). Carcinogenesis
View on PubMed→Frequently Asked Questions
Related Pages
Hair Relaxer Uterine Cancer
Uterine cancer is the primary injury in the hair relaxer litigation. The NIH Sister Study found a 155% increased risk (HR 2.55) for frequent users. Approximately 67,000 Americans are diagnosed with uterine cancer annually.
Hair Relaxer Endometriosis
Chemical hair relaxers contain EDCs linked to endometriosis — a painful condition where uterine-like tissue grows outside the uterus. Phthalates and parabens in relaxers promote endometrial implant growth through estrogen mimicry.
Hair Relaxer Settlement Amounts
No hair relaxer cases have settled or gone to trial yet. Attorney estimates project $90,000–$1,000,000+ depending on injury type and severity. Bellwether trials expected in 2027 will establish actual case values.
L'Oréal Hair Relaxer Lawsuit
L'Oréal is the primary defendant in the hair relaxer MDL through its subsidiary SoftSheen-Carson, maker of Dark & Lovely and Optimum Care. L'Oréal is the world's largest beauty company with €38+ billion in annual revenue.
Revlon Dark and Lovely Lawsuit
Revlon is a defendant in the hair relaxer MDL despite filing bankruptcy in 2022. Revlon maintains insurance coverage and allocated ~$44 million for hair relaxer claims in its reorganization plan. Products include Creme of Nature and Revlon Realistic.
Hair Relaxer Chemical Exposure
Hair relaxers contain at least 45 endocrine-disrupting chemicals across 10 chemical classes. 84% of these chemicals are NOT listed on product labels. The chemicals enter the body through the scalp, whose protective barrier is compromised by the relaxing process itself.
Hair Relaxer Lawsuit Black Women
Hair relaxer lawsuits disproportionately affect Black women, who were the primary marketing target, comprise 60% of affected users, and face twice the uterine cancer mortality rate of white women. This is both a product liability and a racial justice case.
Hair Relaxer Cancer Lawsuits Lawsuit
Chemical hair relaxers and straighteners contain endocrine-disrupting chemicals (EDCs) — including phthalates, parabens, formaldehyde, and cyclosiloxanes — that mimic estrogen and disrupt the hormonal system. The NIH/NIEHS Sister Study (2022) found that women who frequently used these products faced more than double the risk of uterine cancer. Over 14,700 lawsuits are consolidated in MDL 3060 in the Northern District of Illinois, with bellwether trials expected in 2027. The litigation disproportionately affects Black women, who were the primary marketing target and comprise approximately 60% of affected users.
View full case overview